Massachusetts, USA-based clinical stage biotech Rgenta Therapeutics, which is developing a new class of oral small molecules ...

With a novel approach, EMBL scientists discovered important interactions between molecular machines, potentially offering new ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...

Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

NASA's latest findings reveal that RNA's role in life's preference for left-handed proteins may be less about chemical bias ...

An international research collaboration has shed new light on the molecular basis of gene expression, the fundamental biological process that underpins how all organisms use their genetic information.